Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation

Front Immunol. 2023 Sep 25:14:1282155. doi: 10.3389/fimmu.2023.1282155. eCollection 2023.

Authors

Affiliations

¹ UCB Pharma, Cambridge, MA, United States.
² Ra Pharmaceuticals, Cambridge, MA, United States.
³ UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2023.1213920.].

Keywords: C5 R885 variants; C5 cleavage; C5b6; MAC formation; RBC hemolysis; complement activation; macrocyclic peptide inhibitor; permeability.

Copyright © 2023 Tang, Tang, Dhamnaskar, Hoarty, Vyasamneni, Vadysirisack, Ma, Zhu, Wang, Bu, Cong, Palmer, Duda, Sayegh and Ricardo.

Publication types

Published Erratum